SectorPharmaceutical
Established Date25/01/2022
Listing Date20/01/2023
ExchangeNASDAQ Stock Exchange
Full-time Employees5
Fiscal Year Ends31/12
Security TypeCommon stock
Office address822 A1A North, Suite 306, Ponte Vedra, Florida 32082
Business
IntroductionCadrenal Therapeutics, Inc., was registered as a Delaware corporation on January 25, 2022. The company is developing the company's drug candidate ticafalin for unmet need in anticoagulation therapy. Ticafalin is an advanced novel oral and reversible anticoagulant (blood thinner) for the prevention of heart attack, stroke, and death from blood clots in patients with rare cardiovascular diseases that require chronic anticoagulation.
